Drug, bio-affecting and body treating compositions inventions 09/06

20060210474 - Cytotoxicity mediation of cells evidencing surface expression of cd63: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The...

20060210475 - Humanized l243 antibodies: Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies, pharmaceutical compositions containing such antibodies, and clinical therapuetic and diagnostic, as well as research-related uses for such antibodies, are provided....

20060210473 - Vegf-conjugate combined methods for tumor vasculature targeting and tumor treatment: The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example,...

20060210476 - Metabonomics homogeneity analysis: A metabonomic method of selecting one or more non-human primate subjects for inclusion in a study is disclosed. The method generally involves spectroscopically profiling a sample of bodily fluid acquired from a subject proposed to be included in the study. The subject is accepted or rejected as a member of...

20060210477 - Therapeutic agent for cancer: There is provided a therapeutic agent for cancer mainly comprising a saccharide having an α1→3 steric structure where an action of NKT cells on NKR-P1 (natural killer receptor P1) which is a natural killer (NK) cell antigen receptor of NKT cells in an activating ability of natural killer T (NKT)...

20060210478 - Steady state perfusion methods: Methods for assessing ischemic coronary artery disease are provided. The methods include administering a contrast agent that binds to a serum protein component to an animal and obtaining an MR image of the animal's myocardium during a period when the animal is experiencing hyperemia....

20060210479 - Targeting chelants and chelates: Novel chelants and other compounds, and compositions thereof are provided, that are useful for detection and treatment of cancer and other abnormal and disease-state cells and tissues....

20060210480 - Treatment of reduction of dysphagia: The present invention provides methods of treating or reducing dysphagia in patients. In one aspect of the invention, such method comprises administering to a patient in need of such treatment or reduction an amount of an agent sufficient to produce a therapeutically effective aversive taste response. In other aspects, such...

20060210484 - Buccal, polar and non-polar spray containing testosterone: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide testosterone for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, testosterone or a pharmaceutically acceptable ester thereof,...

20060210482 - Chemical composition and method for cold and sinus relief: A chemical composition and method for treatment of the common cold, sinusitis and other conditions associated with nasal congestion is provided. The chemical composition is made of predetermined concentrations of thymol, alcohol, eucalyptol, menthol, methyl salicylate, a preservative, saline solution and a buffer. The method includes the step of administering...

20060210481 - Medicament dispenser: A component of a medicament dispenser has a surface which, in use of the dispenser, contacts a medicinal formulation contained in the dispenser, said surface being presented by a fluorinated polymeric composition having CF3CHFCF3 as a monomer thereof....

20060210483 - Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections: A method of treatment and prevention of upper respiratory illnesses by airborne administration to a subject in need of such treatment a composition containing a therapeutically effective amount of a non-systemic antibiotic....

20060210485 - Pharmaceutical formulations: The invention relates to the use of calcium stearate to inhibit or reduce chemical interaction between an active ingredient substance and a carrier in a solid pharmaceutical formulation, wherein the active ingredient substance is susceptible to chemical interaction with the carrier. An inhalable solid pharmaceutical formulation comprising (a) an active...

20060210486 - Aerosol antiperspirant with polyamide: An aerosol antiperspirant/deodorant comprising: (a) a solvent system for the gellant in an amount of up to 36% of the total formula; (b) from 0.1-1.5% by weight based on the total weight of the composition of at least one siliconized polyamide as a gellant; (c) an antiperspirant active used in...

20060210487 - Hair wax products containing waxes, non-volatile oils and volatile hydrophobic materials: The wax product for treating or setting up a hairstyle or hairdo includes a composition containing at least one wax or wax-like substance, at least one non-volatile liquid hydrophobic oil and at least one volatile or easily volatilized hydrophobic substance that is a liquid or gas at room temperature. Because...

20060210489 - Antibacterial 3',5-disubstituted 2,4'-dihydroxybiphenyl compounds, derivatives and related methods: In the structure, R1 and R2 are independently a hydrogen atom or a lower C1-4 alkyl group and R3 and R4 are independently an alkenyl or alkyl group having from 1 to 20 carbon atoms, with the proviso that R3 and R4 are not both 2-propenyl or n-propyl when R1...

20060210490 - Confection for teeth whitening and oral hygiene: Confections for teeth whitening and oral hygiene that comprise a first component including a first bulking agent, an organic acid, and a peroxide, and a second component including a white pigment dissolved in an alkaline solution and combined with a second bulking agent. The first component forms hydrogen peroxide, a...

20060210488 - Teeth whitening candy with tartar removal and breath freshening properties: This invention discloses a teeth whitening candy intended to fill the gap between daily brushing and the need to augment dental hygiene between visits with dental professionals. The candy will enhance the removal of the tartar and plaque, which accumulates after meals. In addition to whitening teeth, the candy will...

20060210491 - Flavoured mouth wash composition: The present invention provides a flavoured product comprising four or more flavour materials having antimicrobial properties and selected from the group comprising nonanol, decanol, nonanal, decanal, amyl propionate, anethole synthetic, anisic aldehyde, basil oil, benzyl benzoate, benzyl butyrate, benzyl formate, camomile oil, cinnamic aldehyde, cis-3-hexenol, clove bud oil, damascone, ethyl...

20060210492 - Use of rifaximin for treatment and prevention of periodontal conditions: An oral preparation used for treatment and prevention of bacterial periodontal conditions consisting of a non-systemic antibiotic; and a method of treatment of periodontal conditions by orally administering to a subject in need of such treatment a composition containing a therapeutically effective amount of rifaximin....

20060210493 - Dental products comprising bone growth enhancing peptide: Dental products such as toothpastes, mouthwash and dental floss are disclosed which products are enhanced by having dissolved, dispersed or coated thereon a compound which promoted bone growth. Preferred compounds are peptide sequences comprising 10 to 50 amino acids are disclosed. The sequences are characterized by containing an integrin binding...

20060210494 - Functionally graded biocompatible coating and coated implant: The present invention provides a biocompatible coating comprising calcium phosphate that is functionally graded across the thickness of the coating. The coating, which preferably includes hydroxyapatite, is particularly useful for coating implants, such as dental or orthopedic implants. The functionally graded coating is generally crystalline near the interface with the...

20060210496 - Compositions for skin protection from ultraviolet damage: A composition for skin protection from ultraviolet damage and for application to skin or hair, including partially hydrolyzed fucoidan, a base, and a radiation protecting agent. The partially hydrolyzed fucoidan may be fucoidan derived from Tongan limu moui seaweed, Japanese kombu seaweed, Japanese mozuku seaweed, or combinations thereof....

20060210495 - Surface-modified zinc oxides: Surface-modified zinc oxides with a BET surface area of 18±5 m2/g and a C content of 0.1 to 5.0 wt. % are prepared by spraying the zinc oxides with the surface-modifying agent or adding this in vapour form and then heat-treating the mixture. They can be employed for the preparation...

20060210499 - Mild bleaching agents with increased lightening power: Bleaching agents for keratin-containing fibers, in particular, human hair, comprising (a) at least one peroxo compound and/or at least one alkalinizing agent chosen from ammonium, alkali metal and alkaline earth metal carbonates, hydrogencarbonates and carbamides (b) hydrogen peroxide, and (c) SiO2 compounds, where the last-mentioned compounds may be optionally hydrated....

20060210497 - Novel resorcinol derivatives: R1 and/or R2 represents hydrogen (H), linear or branched, cyclic or acyclic, saturated or unsaturated C1-C12 alkyl, alkenyl, cycloalkyl, or cycloalkenyl group; n represents 0, 1. When n=0, the ring is a cyclopentyl with or without one heteroatom from O, N or S and/or with or without one double bond....

20060210498 - Novel resorcinol derivatives for skin: R1 represents hydrogen (H), linear or branched, cyclic or acyclic, saturated or unsaturated C1-C12 alkyl, alkenyl, cycloalkyl, or cycloalkenyl group. Preferably, R1 represents hydrogen (H) or a C1 alkyl group (i.e, methyl group). More preferably, R1 represents hydrogen; n represents 0, 1. When n=0, the ring is a cyclopentyl with...

20060210501 - Color cosmetic comprising yerba santa extract: The application discloses and claims a color cosmetic composition providing moisturization, hydration, and lubrication through the use of Yerba Santa fluid extract. Specific formulations for anti shine pressed powder, blush, brow wax, concealer, eye shadow, lipstick and gloss, mascara, shimmer shadow and foundation compositions are disclosed....

20060210500 - Formulations: The present invention relates to formulations for topical applications comprising pigments obtainable by agitating a suspension comprising one or more inorganic pigments and silver oxide, in order to reduce undesirable side effects caused by microorganisms....

20060210502 - Anhydrous antiperspirant composition containing skin softeners: Disclosed is an anhydrous topical antiperspirant composition comprising a dermatologically acceptable carrier and a perspiration reducing effective amount of a particulate antiperspirant salt suspended in the carrier. In addition, the composition includes behenoxy dimethicone and a non-polar, non-volatile liquid emollient oil. Such a composition provides improved skin feel (i.e. softer...

20060210503 - Aromachemicals: R and R1 are each independently H or C1-5 alkyl provided that in formula (I) when R is methyl, R1 is H or C2-5 alkyl. R2 has from 1 to about 12 carbon atoms and is a straight or branched aliphatic group, or a cyclic, heterocyclic or aromatic group. R3...

20060210504 - Compositions and methods for inhibiting eccrine perspiration in humans: Non-pathological, physiologically normal sweating is inhibited through use of an a muscarinic anticholinergic amine that blocks parasympathetic stimuli from cholinergic nerve fibers to an innerved sweat gland. The anticholinergic agent is included in a form adapted to be topically applied to commonly sweaty areas of the body. Side effects are...

20060210505 - Multi-phase personal care composition comprising visually distinct phases: Multi-phase personal care compositions comprise a first phase and a second phase, wherein said first and second phases form a visually distinct pattern. The compositions are intended for moisturizing or conditioning skin or hair and comprise less than about 10%, by weight of the multi-phase personal care composition, of surfactant....

20060210508 - Fragrance delivery system for surface cleaners and conditioners: We claim a fragrance delivery system consisting of a mixture of various polymers oligomers and stabilizers capable of forming a surfactant complex gel dispersion when combined with a cleansing surfactant base and yielding high levels of fragrance deposition onto the skin, hair or other surface such as a textile, from...

20060210509 - Hair conditioner: The present invention generally relates to a silicone-based hair conditioning composition having improved silicone hair conditioner deposition upon the hair. The composition of the invention comprises hair conditioning compositions having dispersed, non-volatile silicone conditioning agents, cationic conditioning agents and at least one nonionic amphiphilic polymer having at least one fatty...

20060210516 - Article with skin protecting and moisturizing compound: An article with skin-protecting and moisturizing compound, comprising a tissue substrate, a base and partially hydrolyzed fucoidan. The partially hydrolyzed fucoidan may be sulfonated. The partially hydrolyzed fucoidan may be derived from Tongan limu moui seaweed, Japanese wakame seaweed, Japanese mozuku seaweed, or combinations thereof....

20060210518 - Composition containing a urea compound and an oxyalkylenated compound: in which: R1, R2, R3 and R4 represent, independently of each another, a hydrogen atom, a C1-C4 alkyl group or a C2-C6 hydroxyalkyl group possibly containing from 1 to 5 hydroxyl groups, in which at least one of the radicals R1 to R4 represents a hydroxyalkyl group, and also the...

20060210519 - Exfoliating and moisturizing composition and method: An exfoliating and moisturizing composition for the skin includes a wax component having a melting point of at least 35° C. and an exfoliant mineral component dispersed in the wax component. The mineral component has a particle size of no more than 3 microns. Minerals may include a clay and/or...

20060210515 - Hair growth formula: A hair treatment composition for topical application to the skin and/or hair, comprising partially hydrolyzed fucoidan and a pharmaceutical carrier. The composition may contain further additives. The carrier may be hydrophyllic or anhydrous. The composition may also include natural components such as honey and/or mangosteen. The composition may also include...

20060210513 - Method of using skin compositions including tensioning polymers: The invention features a method of treating at least one sign of aging on the skin selected from the group consisting of (i) thickening the skin, (ii) enhancing the barrier function of skin, and/or (iii) treating at least one sign of aging on the skin selected from the group consisting...

20060210511 - Methods of treating skin and mucosal tissue atrophy using compositions including tensioning polymers: The present invention features a method of treating atrophy of skin or mucosal tissue by administering to skin or mucosal tissue in need of such treatment a composition including a tensioning polymer, said method selected from the group consisting of thickening said skin or mucosal tissue, enhancing extracellular matrix production...

20060210510 - Nucleic acid molecules coding for a dextran-saccharase catalysing the synthesis of dextran with alpha 1,2 osidic sidechains: The invention relates to an isolated polypeptide with an glycosyl transferase enzymatic activity for producing dextrans with α(1→2) sidechains, comprising at least one region for bonding to glucan and a catalytically active region situated beyond the region bonding to glucan. The invention further relates to polynucleotides coding for said enzymes...

20060210517 - Skin cleansing article: A skin care article including a carrier and a moist application that includes partially hydrolyzed fucoidan. The partially hydrolyzed fucoidan may by sulfonated. The present invention also discloses a method of making a skin care article by partially hydrolyzing fucoidan, mixing it with a base and applying it to a...

20060210512 - Skin compositions including tensioning polymers: The invention features an emulsion composition including (i) at least about 35% by weight water and (ii) at least about 2% by weight of at least one tensioning polymer having a contractile force greater than about 3 grams/milligram and a water-resistance index from about 0.9 to about 1.9....

20060210514 - Skin protection and moisturizing compositions and method of making the same: Compositions and methods relating to partially hydrolyzed fucoidan for use in skin care compositions are described. Fucoidan from brown seaweeds is partially hydrolyzed and then mixed with other ingredients for use as a skin care composition in cream, lotion, ointment, or other form. The fucoidan is partially hydrolyzed with acid...

20060210520 - Macadamia lipid based surfactants and derivatives and process for preparing same: Novel macadamia-lipid based esters, derivatives, surfactants and emollients are disclosed, as well as their use in the production of surface active derivatives or non-surface active esters and ester emollients. The esters, surfactants and fatty derivatives are useful as emollients, dispersants, emulsifiers, and conditioners for hair care and skin care products....

20060210521 - Composition containing a urea compound and an alkyl glycol carboxylate compound: v

20060210522 - Lipid composition and skin care formulation containing the same:

20060210507 - Cosmetic composition comprising at least one sulphonic polyester and at least one polyurethane: Disclosed herein is a cosmetic composition comprising, in a cosmetically acceptable medium, at least one water-dispersible sulphonic polyester and at least one high molecular weight polyurethane. Also disclosed herein is a method for shaping, fixing, and/or holding the hair comprising applying this cosmetic composition to the hair....

20060210506 - Organopolysiloxane hair treatment agent and hair cosmetic containing the treatment agent: s

20060210523 - Compositions of marine botanicals to provide nutrition to aging and environmentally damaged skin: The present invention relates to novel methods and compositions comprising marine botanicals for treating aged, mature, nutritionally-compromised, or environmentally-damaged skin. These methods and compositions provide improvements in the skin's visual appearance, physiological functions, clinical properties, and biophysical properties....

20060210524 - Skin care composition: Skin care compositions for the care of wrinkles including partially hydrolyzed fucoidan, a base, and an anti-wrinkle compound. The partially hydrolyzed fucoidan may be sulfonated. The partially hydrolyzed fucoidan may be derived from Japanese mozuku seaweed, Japanese kombu seaweed, or Tongan limu moui seaweed. Also disclosed is a method of...

20060210525 - Dispersions: The invention relates to new dispersions, especially for underwater paints, containing (a) a microencapsulated anti-fouling component and (b) an organic solvent....

20060210526 - Conjugated biological molecules and their preparation: Novel biologically active compounds of the general formula (I) in which one of X and X′ represents a polymer, and the other represents a hydrogen atom; each Q independently represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; or, if...

20060210527 - Cyclodextrin-based polymers for therapeutics delivery: The present invention relates to novel compositions of therapeutic polymeric compounds designed as carriers for small molecule therapeutics delivery and pharmaceutical compositions thereof. In some embodiments, the small molecule therapeutic is attached to the polymer by a photocleavable linker. The polymeric compounds may also employ targeting agents. By selecting from...

20060210529 - Method of attenuating neurogenic bruise formation: The present invention provides a method of attenuating the formation or reducing the severity of a neurogenic bruise in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in an amount...

20060210528 - Therapy for tropical diseases: Disclosed are methods and formulations for the treatment of topical conditions on mammalian tissues such as skin and mucous tissues mediated at least -in part by viral, bacterial or fungal infections in the mammal. The methods of this invention involve the in situ formation of a polymeric film over the...

20060210530 - Polymer coating of cells: Polymers and methods of making them are described. The polymers may be used to coat living cells. The polymer-coated cells are useful in cell therapy applications....

20060210531 - Agent eleveting dendritic cell precursor level in blood: Although the fields of therapeutic applications of dendritic cells are now expanding, dendritic cell precursors exist only in a small amount in the peripheral blood and, therefore, it is still difficult to obtain them in a therapeutically useful amount even though they are proliferated in vitro. Therefore, it is a...

20060210532 - Means and methods for the recruitment and identification of stem cells: Described are methods of modulating stem/progenitor cell recruitment involving molecules that agonize the formation of plasmin stimulating the recruitment of stem/progenitor cells, including hematopoietic and endothelial precursor cells. Conversely, antagonists of plasmin can inhibit recruitment of the stem cells. In addition, the identification of the uPA receptor (uPAR) as a...

20060210533 - Compounds and compositions for delivering active agents: Oxadiazole compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well....

20060210534 - Pegylated interleukin-10: Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus...

20060210539 - Anti-angiogenic methods and compositions: Disclosed herein are methods and compositions for treatment of conditions requiring inhibition of angiogenesis. Such conditions include those characterized by neovascularization, such as retinopathies, macular degeneration and various malignancies....

20060210540 - Compositions and methods for enhancing the immunogenicity of antigens: The present invention provides recombinant polypeptides comprising an N-terminal fragment of an ActA protein or LLO protein fused to an antigen or a fragment thereof, nucleotides encoding same, recombinant vectors comprising same, and immunogenic and therapeutic methods utilizing same....

20060210535 - Means for regulating the expression of human isoforms of ant: ARNi which can selectively inhibit expression of an isoform of ANT, characterized in that said ARNi are an ARN duplex, one of the strands being highly homologous to a fragment of ARNm coding for said isoform of ANT....

20060210536 - Methods and compositions for inhibiting stat signaling pathways: The invention relates to compositions and methods for modulating cell signaling mediated by signal transducers and activators of transcription (STAT). The compositions target cellular STAT3 and STAT1 protein, particularly STAT3, for degradation via the ubiquitination pathway. Thus, the STAT inhibiting agents are useful for inhibiting STAT mediated signal transduction events,...

20060210541 - Methods for treating and preventing vascular disease: Methods for treating and/or preventing vascular disease are disclosed. The methods use gene delivery techniques to deliver nucleic acid molecules encoding anti-inflammatory cytokines to a subject....

20060210537 - Theileria parva dna vaccines: The present invention relates to recombinant anti-Theileria parva vaccines and the administration of such vaccines to animals, advantageously bovines. Advantageously, the anti-Theileria parva vaccine encompasses a recombinant avipox virus that includes a nucleotide sequence encoding a Theileria parva gene. The invention further relates to methods of vaccinating animals, advantageously bovines,...

20060210538 - Use of apotosis inhibiting compounds in degenerative neurological disorders: The invention provides methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain associated with a neurodegenerative diseases that is characterized by an excess buildup of buildup of intracellular protein aggregates. In particular, the invention provides methods and compositions used...

20060210544 - Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient: Intravenous administration of bone marrow cells collected from rat bone marrow or peripheral blood to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or...

20060210545 - Process for treating spirulina: The treatment of spirulina by a process which includes placing spirulina that has not been previously heat-sterilized, lactic acid bacteria and sugar in water, then culturing the lactic acid bacteria provides treated spirulina in which the distinctive taste and odor of spirulina are minimized, in which active ingredients such as...

20060210543 - Method of treating infarcted myocardium: A method of treating an infarcted myocardium, the method comprising administering to the myocardium of a subject in need thereof a therapeutically effective amount of osmotically activated immune cells, thereby treating the infarcted myocardium....

20060210542 - Use of tpo mimetic compounds and pharmaceutical compositions in the treatment of anemia: A method of treating anemia is disclosed. The method includes administering a TPO mimetic compound to a subject. Pharmaceutical compositions including a TPO mimetic compound and a pharmaceutically acceptable carrier as well as diagnostic methods employing a labeled TPO mimetic compound are also disclosed....

20060210546 - Athlete dietary supplement: A vitamin supplement to temporarily enhance the abilities of a individual during a sport activity which includes a plurality of B family vitamins and one or more other vitamins, minerals, and/or natural ingredients....

20060210547 - Dna encoding anti-apoptotic protein and recombinant 30k protein: The present invention relates to DNAs encoding anti-apoptotic 30K proteins. More particularly, the present invention is directed to 30K protein genes and a recombinant proteins prepared by using novel anti-apoptotic gene obtained from silkworm. The present invention also provides anti-apoptotic health care food, pharmaceutical preparation, additive for cell culture medium,...

20060210549 - Controlled release liposomes and methods of use: The present invention provides liposomes that include a trigger polypeptide, a lipid layer, and a compartment surrounded by the lipid layer and methods of using the liposomes....

20060210548 - Method for reducing obstructive hydrocephalus: A process for reducing cerebrospinal fluid flow obstruction includes the administration of a therapeutic dose of a clot-reducing agent to a subject having preconditions or obstructive hydrocephalus symptoms. The dose is maintained within the subject for a period of time sufficient to reduce cerebrospinal fluid flow obstruction. The clot-reducing agent...

20060210550 - Angiogenesis inducer: It is intended to provide an angiogenesis inducer comprising fibrin which is safe to a living body. The angiogenesis inducer is characterized by being capable of safely inducing angiogenesis when administered to a living body, which makes it possible to achieve functional regeneration of living tissues or organs suffering from...

20060210552 - Compositions and methods for systemic inhibition of cartilage degradation: Methods and compositions for inhibiting articular cartilage degradation. The compositions preferably include multiple chondroprotective agents, including at least one agent that promotes cartilage anabolic activity and at least one agent that inhibits cartilage catabolism. The compositions may also include one or more pain and inflammation inhibitory agents. The compositions may...

20060210551 - Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of a patient subjected to thrombolyses: The invention concerns the use of a mast cell activation- or degranulation-blocking agent in the manufacture of a medicament for preventing and treating cerebral complications caused by thrombolytic treatment. The invention also relates to treatment of patients suffering from cerebral complications associated with thrombolysis. Further, the invention provides thrombolytic compositions...

20060210553 - Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excesssive cell proliferation: The present invention relates to the use of the alkaloid K252 and its analogues or derivatives to prepare topical drugs for the treatment of disorders characterised by hyperproliferation of keratinocytes....

20060210554 - Detection of cholesterol ozonation products: The invention relates to detection of cholesterol ozonation products that are generated by atherosclerotic plaque material, and to methods of detecting vascular conditions that relate to the accumulation and oxidation of cholesterol....

20060210555 - Compositions comprising immunoreactive reagents and saponins, and methods of use thereof: The present invention relates to pharmaceutical compositions that are useful for the prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response, and methods of...

20060210556 - Novel composition and methods for the treatment of immune disorders: The present invention relates to compositions of matter and methods for the treatment and diagnosis of immune related diseases, including those mediated by cytokines released primarily either Th1 or Th2 cells in response to antigenic stimulation. The present invention further relates to methods for biasing the differentiation of T-cells in...

20060210557 - Stabilized liquid polypeptide formulations: The present invention provides formulations for maintaining the stability of polypeptides, in particular, therapeutic antigen-binding polypeptides such as antibodies and the like, for example, anti-Aβ antibodies. The formulations generally include an antioxidant in a sufficient amount as to inhibit by-product formation, for example, the formation of high molecular weight polypeptide...

20060210558 - Hematopoietic cell selectin ligand polypeptides and methods of use thereof: The invention feature methods and compositions for treating inflammatory disorders, hematopoietic disorders and non-hematopoietic disorders (e.g., non-hematopoietic cancers) and for isolating cells (e.g., stem cells) in a mammal....

20060210561 - Dosages for treatment with anti-egfr antibodies: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody....

20060210559 - Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use: Disclosed herein are nucleic acid sequences that encode polypeptides. Also disclosed are antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving...

20060210560 - Tnf receptor action modulaton: A method of modulating signal transduction and/or cleavage in Tumor Necrosis Factor Receptors (TNF-Rs) is provided. Peptides or other molecules may interact either with the receptor itself, or with effector proteins interacting with the receptor, thus modulating the normal functioning of the TNF-Rs. Such peptides or other molecules may be...

20060210563 - Administration of anti-cytokine f(ab')2 antibody fragments: The present invention is directed to a method of treating a cytokine-mediated immune reaction in a patient in need of such treatment by administration of an effective amount of anti-cytokine F(ab′)2 antibody fragments. The antibody fragments are preferably free from albumin and of whole antibodies, as well as substantially free...

20060210565 - Antagonists of hmg1 for treating inflammatory conditions: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring...

20060210566 - Methods of treating anemia by inhibition of vascular endothelial growth factor (vegf): Methods of treating anemic disorders in human subjects comprising administering a VEGF antagonist comprising a fusion polypeptide having an immunoglobulin-like (Ig) domain 2 of the VEGF receptor Flt1 and Ig domain 3 of the VEGF receptor Flk1 or Flt4, and a multimerizing component. Further included are methods of preventing anemia,...

20060210564 - Novel diabody-type bispecific antibody: The purpose of the present invention is to provide a diabody-type bispecific antibody, which is characterized by having low immunogenicity and high infiltrating activity into tumor tissues, and by being easily mass-produced at a low cost with use of microorganisms, and by being easily altered in function by means of...

20060210562 - Treatment of type 1 diabetes before and after expression of predisposition markers: The present invention relates generally to the use of compounds, compositions, combinations, kits, and methods for the effective endocytic presentation of immunosuppressive factors for the down regulation of diabetogenic T cells for the treatment of type I diabetes....

20060210567 - Antibodies against pd-1 and uses therefor: This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders,...

20060210569 - Antibodies inhibiting transportation activity of peptide transporter: The present inventors discovered that the PepT-binding antibodies have the ability to inhibit the transport activity of peptide transporters, as a result of dedicated research. These antibodies may be utilized as cell growth inhibitors, for example, for treating and preventing cancer....

20060210571 - Engineering antibodies that bind irreversibly: The present invention provides a mutant antibody comprising a reactive site not present in the wild-type of the antibody and a complementarity-determining region that specifically binds to a metal chelate, wherein the reactive site is in a position proximate to or within the complementarity-determining region....

20060210568 - Methods and compositions for cancer treatment: Methods and compositions for breast cancer treatment and prevention by inducing overexpression of adipose differentiation related protein (ADRP) in the cancer cells. Over expression of ADRP causes breast cancer cells to re-differentiate, whereby cancer cell proliferation and tumorigenesis is inhibited and cancer cells are induced to undergo apoptosis. Also disclosed...

20060210570 - Methods and compositions for modulating prostasin: The invention provides methods and compositions related to modulating prostasin....

20060210573 - Peptide useful in immunomodulation: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to...

20060210572 - Treatment of lymphatic metastatic cancerous lesions: Methods for improving the efficacy of cancer therapy are described. In one embodiment the method involves administering the cancer therapeutic to a first cancer lesion wherein the first cancer lesion is connected through the lymphatic system to a second cancer lesion and wherein the cancer therapeutic can thereby travel to...

20060210574 - Pharmaceutical compositions and articles of manufacture useful in reversal of a clinical epiosode of an incurable disease and methods of use thereof: A method of reversing a clinical episode of a disease which is generally considered incurable in a subject. The method includes providing an immune-globulin preparation containing a detectable titre of antibodies to the disease which is generally considered incurable and administering the immune-globulin preparation to the subject. Preferably, the immune...

20060210575 - Cytotoxic protein and utilization thereof: This invention provides a cytotoxic protein (M toxin) produced by Helicobacter pylori, a partial peptide, and an antitumor agent containing the cytotoxic protein. The protein is obtained by culturing a transformant which is transformed with a recombination vector containing DNA coding the cytotoxin protein. This invention provides further the use...

20060210576 - Method for treating or preventing metastasis of colorectal cancers: Disclosed are methods of identifying agents for treating metastatic lesions of colorectal cancer. Also disclosed are methods for treating metastatic lesions of colorectal cancer and preventing metastasis of colorectal cancer....

20060210577 - Rtvp-glipr-like compositions and methods for the detection, treatment and prevention of prostate cancer: The invention is directed to purified and isolated novel RGL2 polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above....

20060210578 - Immunogenic polypeptide isolated from mycobacterium avium subspecies paratuberculosis and uses therof: The present invention relates to an immunogenic polypeptide isolated from Mycobacterium avium subspecies paratuberculosis and variants of the polypeptide. The polypeptide and variants may be used in vaccines against Johne's disease and in methods for detection of the disease. Antibodies against the polypeptide or variants may be used in diagnostic...

20060210579 - Nucleic acids and proteins from streptococcus groups a & b: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics....

20060210580 - Nucleic acids and proteins from streptococcus groups a & b: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics....

20060210581 - Nucleic acids and proteins from streptococcus groups a & b: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics....

20060210582 - Nucleic acids and proteins from streptococcus groups a & b: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics....

20060210583 - Nucleic acids encoding sarcocystis neurona antigen and uses thereof: The present invention provides novel isolated nucleic acids encoding antigenic proteins derived from Sarcocystis neurona, or unique fragments thereof. In particular, the invention provides novel isolated nucleic acids encoding membrane-associated polypeptides SnSAG2, SnSAG3, and SnSAG 4. Also provided are purified antigenic polypeptide fragments encoded by the novel nucleic acid sequences...

20060210584 - Method for preparing citrinin-free monascus biomass and use of citrinin-free monascus biomass: Disclosed is a method for preparing a citrinin-free Monascus biomass. Also disclosed are a pharmaceutical and a functional food comprising a preparation by the method. The Monascus biomass possesses anti-oxidation property, and shows anti-proliferation property on cancer cells via apoptosis pathway....

20060210585 - Method for the production of hiv-1 gag virus-like particles: The invention describes a vector including a nucleotide sequence encoding an HIV Gag polypeptide for use in the production of HIV-1 Gag virus-like particles. The vector may be a plant vector, for example, a tobacco mosaic virus vector such as the pBSG1057 vector or a tobacco etch virus vector. The...

20060210586 - Recombination bcg vaccine: A recombinant BCG vaccine being transformed with an expression vector that has a polynucleotide encoding a foreign antigenic protein, wherein the polynucleotide is a modified one in which a third position of each codon is substituted with G or C without a change of an amino acid. This recombinant BCG...

20060210587 - Virus-like particles for the induction of autoantibodies: The invention described herein relates to compositions and methods for stimulating immune responses in vivo against a tolerogen. Novel biotechnological tools, pharmaceuticals, therapeutics and prophylactics, which concern chimeric or conjugated virus-like particles, and methods of use of the foregoing are provided for the study of B cell tolerance and the...

20060210588 - Hiv-peptide-carrier-conjugates: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising a VLP which can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs), and particular HIV peptides linked thereto....

20060210589 - Methods for treating myofascial pain: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G....

20060210590 - Minor allergen control to increase safety of immunotherapy: The invention discloses a method for standardizing allergen extract with respect to the contents of major as well as minor allergens. The method comprises determining relative amounts of allergens in a given extract, followed by an adjustment of the contents of major an minor allergens so as to meet predefined...

20060210591 - Immunization of an individual against carcinomas and the preliminary stages thereof: The present invention relates to a pharmaceutical composition, comprising a cell cycle regulatory protein and/or an expressible nucleic acid coding for this in an amount suitable for immunization of an individual against carcinomas and the preliminary stages thereof and common auxiliary agents and/or to the use of a cell cycle...

20060210592 - Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis: An oral preparation consisting of a non-systemic antibiotic and a proton pump blocker used for prevention of aspiration pneumonia and sepsis; and a method of prevention of aspiration pneumonia and/or sepsis by orally administering to a subject in need of such treatment a composition containing a therapeutically effective amount of...

20060210593 - Methods of making and methods of using antiseptic disinfectant, cosmetic and toiletries, medicine or food containing the same: The present invention relates to methods for producing and using antiseptic disinfectant, cosmetic and toiletries, medicine or food and method for antiseptically disinfecting a cosmetic and toiletries, medicine or food. The cosmetic and toiletries, medicine or food contain an antiseptic disinfectant comprising 1,2-alkanediol with 5-10 carbons and a fragrance component,...

20060210594 - Composite spinal nucleus implant with water absorption and swelling capabilities: Embodiments relate to a spinal nucleus implant with water absorption and swelling capabilities, compositions for producing the spinal nucleus implants, and methods of preparing and using the spinal nucleus implants. The spinal nucleus implant can be created from a composition comprising a mixture of non-hydrogel polymer material and at least...

20060210595 - Device containing cytophilic islands that adhere cells separated by cytophobic regions: The invention provides a device for adhering cells in a specific and predetermined position, and associated methods. The device includes a plate defining a surface and a plurality of cytophilic islands that adhere cells, isolated by cytophobic regions to which cells do not adhere, contiguous with the cytophilic islands. The...

20060210599 - High viscosity liquid controlled delivery system and medical or surgical device: The present invention relates to novel nonpolymeric compounds and compositions that form liquid, high viscosity materials suitable for the delivery of biologically active substances in a controlled fashion, and for use as medical or surgical devices. The materials can optionally be diluted with a solvent to form a material of...

20060210597 - Prosthetic implants including ecm composite material: Described are preferred prosthetic valve devices including a first extracellular matrix material having a second extracellular matrix material deposited thereon. The preferred materials are made by culturing cells in contact with an extracellular matrix graft material in a fashion to cause the cells to biosynthesize and deposit extracellular matrix components...

20060210598 - Resorbable structure for treating and healing of tissue defects: Devices and processes (e.g., improved Plasticized Melt Flow processes (PMF) or improved Phase Separation Polymer Concentration (PSPC), etc.) used to make resorbable and non-resorbable structures for treating and/or healing of tissue defects are disclosed. Among the advantages of using these improved processes are the preservation of molecular weight and the...

20060210596 - Seeding implantable medical devices with cells: Apparatus and methods for seeding an implantable medical device, such as a vascular prosthesis, with cells, such as endothelial cells, are described. The invention supports techniques for seeding a luminal surface of the device with axial centrifugation. Cells are introduced in suspension into the lumen of the device. The introduction...

20060210600 - Coated stent with timed release of multiple therapeutic agents to inhibit restenosis adjacent to the stent ends: The present invention provides a system for treating a vascular condition that inhibits restenosis adjacent to the ends of a stent by delivering a therapeutic agent to the vessel wall at and beyond the stent ends. The system comprises a catheter and a coated stent operably coupled to the catheter....

20060210602 - Compositions and systems for forming crosslinked biomaterials and methods of preparation and use: Crosslinkable compositions are provided that readily crosslink in situ to provide biocompatible, nonimmunogenic crosslinked materials that may be used as adhesive compositions. The compositions comprise collagen and a plurality of crosslinkable components having reactive functional groups thereon, with the functional groups selected so as to enable inter-reaction between the components,...

20060210603 - Implantable medical articles having laminin coatings and methods of use: Laminin-containing coatings for the surfaces of implantable medical devices are disclosed. The coatings promote the formation of vessels in association with the coated surfaces with minimal fibrotic resonse....

20060210601 - Stretchable collagen material and manufacturing method and use thereof: The present invention provides a stretchable collagen material, particularly collagen derived from fishes, having excellent stretching property and mechanical strength, which can be widely used as a cell carrier and medical material, and to a method for manufacturing the same. By thermally treating a gel comprising collagen fiber cross-linked by...

20060210604 - Ocular delivery of polymeric delivery formulations: The present invention provides a flowable composition suitable for use as a controlled release implant. The flowable composition can be administered into the ocular region of a mammal. The composition includes: (a) a biodegradable, biocompatible thermoplastic polymer that is at least substantially insoluble in aqueous medium, water or body fluid;...

20060210605 - Devices, systems and methods useable for treating sinusitis: Sinusitis and other disorders of the ear, nose and throat are diagnosed and/or treated using minimally invasive approaches with flexible or rigid instruments. Various methods and devices are used for remodeling or changing the shape, size or configuration of a sinus ostium or duct or other anatomical structure in the...

20060210606 - Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood: The present invention aims at preventing or retarding a transition to hemodialysis treatment in kidney failure or decreasing the number of implementation of the hemodialysis therapy and preventing or lessening occurrence of accompanying hyperammonemia in hepatic insufficiency. To accomplish the purposes described above, the pathological improvement food of the invention...

20060210609 - Fucoidan compositions and methods for dietary and nutritional supplements: Compositions and methods relating to partially hydrolyzed fucoidan for use in dietary supplements are described. Fucoidan from brown seaweeds is partially hydrolyzed and then mixed with other ingredients for use as a dietary supplement in beverage, capsule, or tablet form. The fucoidan is partially hydrolyzed with acid and heat. The...

20060210610 - Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use: Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use are disclosed....

20060210608 - Mineral composition: The present invention relates to a mineral composition, characterized in that the mineral composition comprises 100 parts by weight of a metal salt having a solubility product in water at 25° C. of 1.0×10−7 or less and 0.5 to 50 parts by weight of an emulsifier having an HLB of...

20060210607 - Water-soluble isoflavone composition, process for producing the same, and use thereof: An isoflavone composition which contains an α-glucosyl isoflavone and isoflavone and optionally an isoflavone aglycone, wherein the ratio of the amount of aglycone in the isoflavone and the isoflavone aglycone in total to the amount of aglycone in the α-glucosyl isoflavone [(the amount of aglycone in α-glucosyl isoflavone)/(the amount of...

20060210611 - Fat soluble vitamin feed supplements and processes for delivering same: A process is disclosed for delivering a stable, fat soluble vitamin to a feed composition. The process includes dissolving a fat soluble vitamin in a solvent to form a vitamin-enriched solvent and combining the vitamin-enriched feeds; processes for supplementing the diet of a feed animal with a fat soluble vitamin,...

20060210612 - Make-up-removing article: An article containing:(A) a water-insoluble hydrophilic polyurethane foam support, and, impregnated on the support,(B) a composition containing separate, non-emulsified aqueous and oily phases, the aqueous and oily phases being present in a ratio by weight ranging from 25/75 to 90/10 (aqueous/oily), the oily phase having a melting point of less...

20060210614 - Method of treatment of a metabolic disease using intranasal administration of exendin peptide: Methods for treating metabolic diseases are described for intranasal delivery of an exenatide, comprising an aqueous mixture of exendin, and a delivery enhancer selected from the group consisting of a solubilizer, a chelator, and a surfactant, and the pharmaceutical formulations used therein....

20060210613 - Therapeutic wound care product: The present invention relates to a multi-layered product having at least one therapeutic agent therein and a layer containing a chitin or chitin derivative for treatment of a wound, and also to a method using such product....

20060210615 - Dermal or transdermal therapeutic system comprising an ormocer with barrier effect on a cover foil: The invention relates to a dermal or transdermal therapeutic system comprising a cover foil with barrier effect against gas, odour and volatile light substances. Said invention is characterised in that the cover foil is provided with at least one substrate and with at least one layer consisting of an inorganic-organic...

20060210617 - Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl: Silicone adhesive formulations are provided, in which fentanyl particles are suspended one or more a solvated silicone adhesives. The formulations can be used for manufacturing improved, matrix-type transdermal devices for administering fentanyl....

20060210616 - Therapeutic patch for ophthalmologic and cosmetic use: This invention is directed to a therapeutic patch for ophthalmologic and cosmetic use that provides therapy to the region where the patch is provided; the therapeutic patch provides a therapeutic delivery surface for placement against, for example, the eyelid and peri-orbital structures of a patient, and a non-contacting surface that...

20060210619 - Limposomes containing asiaticoside and the uses thereof: This invention belongs to the chemical field, which is related to the fields of pharmaceutical preparations and cosmetic, especially to asiaticoside-liposome and its use for preparing pharmaceutical preparations and cosmetic. In this invention, asiaticoside and lipid components are fused by heating or dissolved in organic solvents, then treated with the...

20060210618 - Phospholipid derivatives and process for the production there: wherein [PG]k represents a residue of polyglycerin having a polymerization degree of k, wherein k is 2 to 50, R1CO and R2CO independently represent an acyl group having 8 to 22 carbon atoms, symbol “a” independently represents an integer of 0 to 5, symbol “b” independently represents 0 or 1,...

20060210620 - Co-precipitated amorphous losartan and dosage forms comprising the same: The technical field of the invention relates to spray dried, co-precipitate amorphous losartan dosage forms that are stable over time and processes for their preparation. The processes stabilize the amorphous losartan. The process includes preparing an aqueous solution of losartan and one or more hydrophilic polymers; and spray drying the...

20060210621 - Solid dosage form for providing a dietary supplement: Compositions and methods relating to partially hydrolyzed fucoidan for use in dietary supplements are described. Fucoidan from brown seaweeds is partially hydrolyzed and then mixed with other ingredients for use as a dietary supplement in beverage, capsule, or tablet form. The fucoidan is partially hydrolyzed with acid and heat. The...

20060210622 - Surface modified particulate compositions of biologically active substances: This invention disclosure relates to compositions for the delivery of stable surface modified sub-micron and micron sized particles of water-insoluble biologically active substances from a non-aqueous medium that self-disperses on exposure to an aqueous environment....

20060210623 - Sustained release delivery of isradipine: Sustained release oral formulations of israpidine, methods of preparing same, and methods of using sustained release oral formulations to provide controlled delivery of israpidine. The sustained release oral formulations include israpidine and a sustained release polymer, and provide substantially zero order release of israpidine over an extended period....

20060210624 - Combination product comprising an antagonist or inverse agonist of histamine receptor h<sb>3 </sb>and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of p: Medicament comprising, in a pharmaceutically acceptable vehicle, an anti-psychotic or an antidepressant (A), which, on its own, has an undesirable effect of a gain in body weight or sedation, and an antagonist and/or inverse agonist (B) of the histamine H3 receptor, the antagonist and/or inverse agonist of the histamine H3...

20060210627 - Direct compression formulation and process: This invention relates to tablets especially tablets formed by direct compression of a dipeptidylpeptidase IV (DPP-IV) inhibitor compound, a process for the preparation thereof, to new pharmaceutical formulations, and new tableting powders comprising DPP-IV inhibitor formulations capable of being directly compressed into tablets. The invention relates further to a process...

20060210626 - Radio frequency identification pharmaceutical tracking system and method: An ingestible dosage form includes a pill containing a pharmaceutical content and an RF tag associated with the pill. The RF tag is configured to output a wireless response signal in response to a wireless excitation signal received by the RF tag from an RF reader. The ingestible dosage form...

20060210625 - Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms: An oral pharmaceutical composition, comprising one or more positively charged, highly water-soluble pharmaceutically active agents such as trospium chloride, and one or more polymers containing polarized oxygen atoms, whereby the active agent(s) form an ion-dipole interaction with the polymer(s) that may be used for an immediate release system, an extended...

20060210628 - Use of epinine for enhancing physical performance: A method of decreasing fat and adipose tissue, and increasing alertness in humans comprises administering epinine in a daily dosage between about 50 and 300 mg. Epinine may be administered once per day or in multiple doses, either alone or in combination with other compounds and mixtures....

20060210630 - Controlled release compositions of gamma-hydroxybutyrate: The present invention is directed to oral pulse-release pharmaceutical dosage form containing an immediate release component of gamma-hydroxybutyric acid, and one or more delayed/controlled release components of gamma-hydroxybutyric acid....

20060210629 - Zinc-containing sustained-release composition, its preparation, and method for producing the same: With a simple and high-yield production method, a zinc-containing sustained-release composition capable of stabilizing a physiologically active protein or peptide, typically G-CSF by precipitation and retaining drug efficacy for several days in a living body owing to its sustained releasability is provided. Concretely, a zinc-containing sustained-release composition produced by forming...

20060210631 - Multi-particulate, modified-release composition: A multi-particulate, modified-release pharmaceutical composition for the oral administration of an active ingredient to the colon, wherein said particles comprise: (a) a core comprising an active ingredient or a pharmaceutically acceptable salt or ester thereof, and optionally one or more excipients; (b) a first coating applied to the surface of...

20060210632 - Sublingual coated tablet of fentanyl: The present invention relates to a fentanyl coated tablet and to the method for the preparation thereof....

20060210633 - Programmed drug delivery system: The present invention provides a programmed drug delivery system comprising: (a) a core composition comprising one or more beneficial agents and pharmaceutically acceptable excipients, wherein at least one excipient swells when exposed to an aqueous environment, (b) a coat surrounding the core composition, wherein the coat is impermeable to the...

20060210634 - Ceramic structures for controlled release of biologically active substances: The present invention provides compositions for controlled drug delivery, dosage forms, and processes for producing dosage forms. In a composition aspect of the present invention, a composition including a drug and a ceramic structure is provided. The ceramic structure has either a hollow portion wherein the drug is included in...

20060210635 - Injectable gel-forming compositions based on cross-linked and non-cross-linked polymers and the use thereof: The invention relates to injectable gel-forming compositions which contain an association of linear and cross-linked polymers and are embodied in the form of a suspension. The use of said compositions, in particular for filling pipes and cavities is also disclosed....

20060210638 - Injectable compositions of nanoparticulate immunosuppressive compounds: The invention is directed to an injectable nanoparticulate immunosuppressant composition for the formation of a subcutaneous or intramuscular depot. The invention is also directed to an injectable composition of nanoparticulate tacrolimus and/or sirolimus which eliminates the need to use polyoxyl 60 hydrogenated castor oil (HCO-60) and/or polysorbate 80 as a...

20060210639 - Nanoparticulate bisphosphonate compositions: Nanoparticulate bisphosphonate compositions, having an effective average particle size of less than 2000 nm, are described. The compositions are useful in treating bone resorption in a mammal....

20060210636 - Nanoscale core/shell particles and the production thereof: In methods for the production of nanoscale particles having a so-called core and at least one so-called shell, either nanoscale particles of an inorganic material having a particle size of <100 nm or nanoscale particles of a magnetic material having a particle size of <100 nm are used as the...

20060210640 - Process for producing nanoparticles by spray drying: Nanoparticles of a compound are produced by spraying a solution of the compound into a heated chamber. The resulting product comprises a free flowing mixture of nanoparticles of the compound....

20060210637 - Stable tablet dosage forms of proton pump inhibitors: This invention relates to a method of making oral formulations of practically water insoluble, or very slightly water soluble proton pump inhibitors, the oral dosage forms so made, and methods of use thereof. The oral dosage form has a core tablet of compressed particles composed of powder particles of a...

20060210641 - Absorbable microparticles: This invention pertains to a sustained release complex of one or more peptides, one or more proteins or a combination thereof immobilized on an absorbable polymer microparticle optionally having an absorbable polymer coating. The microparticle complex of this invention comprises a peptide(s) and/or protein(s) which have at least one amino...

20060210642 - Cardiac development promoting activity of perivitelline fluid of embryos of indian horseshoe crab, tachypleus gigas (muller): The present invention relates to a method for cardiac development activity in a subject comprising administering to the subject an appropriate amount of perivitelline fluid obtained from fertilized eggs of horseshoe crab....

20060210643 - Cartilage repair mixture containing allograft chondrocytes: The invention is directed toward a sterile cartilage defect implant material comprising milled lyophilized allograft cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of sodium hyaluronate, hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran...

20060210644 - Materials, methods, and devices for treatment of arthropathies and spondylopathies: Novel modalities are introduced to treat joint and cartilage ischemia and related pathologies to improve outcome in the treatment of arthropathies and spondylopathies. The invention includes compositions, materials or devices which will improve oxygen, substrate and nutrient delivery to joint tissues and modalities to decrease the degradation of joint tissues...

20060210645 - Pharmaceutically acceptable carrier for ophthalmic compositions: A pharmaceutically acceptable carrier for ophthalmic compositions useful in treating or alleviating the symptoms of dry eye syndrome, elevated intra-ocular pressure, age-related maculopathy or age-related macular degeneration....

20060210646 - Accelerator for mineral absorption and use thereof: The present invention has an object to provide an accelerator for mineral absorption and a composition containing the accelerator. The object is solved by providing an accelerator for mineral absorption comprising cyclic tetrasaccharide and/or saccharide derivatives thereof and a composition containing the accelerator....

20060210647 - Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto: The present invention relates to the discovery that non-traditional export of certain pro-inflammatory cytokines lacking a signal sequence from a cell can be inhibited by copper chelation and/or administration to the cell of a truncated form of S100A13 lacking the basic residue portion. Further, copper chelation inhibits, inter alia, neointima...

20060210648 - Method for treating an inflammation or lesion caused by a virus: A method for treating an inflammation or lesion caused by herpesvirus, comprising topically applying to said inflammation or lesion a composition consisting essentially of a C1 to C3 monohydroxy alcohol or a C2 to C4 diol and a sufficient amount of an acid to adjust the pH of the composition...

20060210649 - Method and kit to cure chronic cough: The current invention is a method and kit to cure chronic cough, which is typically a dry cough. Chronic coughing is frequently caused by gastric acid which has been aerosolized by coughing, thereby causing hypersensitivity of the upper airway, leading to more coughing. This vicious cycle can torture the patient...

20060210650 - Supplemental dietary composition for promoting weight loss: Compositions, and methods for administering the same to humans, are provided for the promotion of healthy fast weight loss while providing an excellent source of calcium and containing antioxidants. The compositions preferably comprise three sources of calcium and include at least one of Calcium Carbonate, Vitamin D, caffeine-free Green Tea,...

20060210651 - Methods and compositions involving aldose reductase: Embodiments of the invention include methods and compositions for the inhibition of Aldose Reductase by nitric oxide. Certain embodiments of the invention include the induction of nitric oxide by administration of a nitric oxide donor, nitric oxide precursor, inhibitor of a nitric oxide synthase inhibitor, and/or an activator of nitric...

20060210652 - Extract of petasites japonicus having neuroprotective effect and antioxidant activity: The present invention relates to an extract of Petasites japonicus having antioxidant activity, and more particularly, to an extract of Petasites japonicus having antioxidant activity which is extracted using an alcohol and an antioxidant for the prevention and treatment of a brain disease comprising the extract as an effective ingredient....

20060210653 - Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition: Compositions and methods for administering the same to humans are provided for the promotion of increasing a person's natural metabolic rate, increasing thermogenesis, increasing training intensity, increasing muscular definition, and/or decreasing water retention. Said compositions comprise, green tea extract, anhydrous caffeine, theobroma cocao extract, oolong tea extract, white tea extract,...

20060210654 - Process for extracting vital components from plants: The present invention presents a cost effective process for separating between liquids extracted from whole plants or plant parts and the solid plant residue, and performing concurrent sterilization of both substances. This novel method comprising fast deep-freezing said whole plant(s) or parts thereof; crushing the deep-frozen whole plant(s), or parts...

20060210655 - Bioactive compositions, natural methods of producing them and computational methods for designing natural production processes: The present invention is directed to procedures for the controlled natural bioprocessing of naturally occurring biological molecules by processing activities present in select organisms, extracts of such organisms or other natural processing agents. The invention also covers the methods for developing these procedures and compositions prepared by the procedures....

20060210656 - Synergistic effects of nuclear transcription factor nf-kb inhibitors and anti-neoplastic agents: The present invention provides methods of inhibiting metastasis of a tumor and methods of treating a tumor using a combination of an inhibitor of the activation of nuclear factor NF-κB and a cancer chemotherapeutic agent. In one embodiment of the present invention, combination of curcumin and paclitaxel (taxol) can be...

20060210657 - Compositions and methods for prostate and kidney health and disorders, an herbal preparation: A composition including an aliquot of the herb Herba Epimedii; and an aliquot of at least three supplemental herbs selected from the group consisting of Fructus Rosae Laevigatae; Fructus Rubi; Fructus Psoralea; Radix Morindae Officinalis; Fructus Schisandrac Chinensis; Fructus Ligustri Lucidi; Semen Cuscutae; and Radix Astragali. A composition including icariin;...

20060210658 - Processes for obtaining (-)-guaiol and the use thereof: A process for obtaining oils of sesquiterpenes and sesquilactones and (−)-guaiol from the oil of Callitris intratropica, processes for encapsulation of the oil from Callitris intratropica, and the various uses of the oil and the encapsulated oil are described. The oils are suitable for various purposes in the personal care...

20060210659 - Anti-obesity agent: The object of the present invention is to provide an active substance which has an anti-obesity effect such as a triglyceride lowering activity, a cholesterol lowering activity and the like. The present invention provides a blood triglyceride lowering agent, a cholesterol lowering agent, a body fat storage suppressive agent, an...

20060210660 - Process for preparing an extract from ivy leaves: The present invention relates to a process for preparing an extract from ivy leaves which includes the active ingredient hederacoside C and α-hederin, and to extracts prepared by this process. According to this there is initially provision of a first, α-hederin-rich extract and subsequently provision of a second, hederacoside C-rich...

20060204435 - Detection, imaging, and depletion of intracellular pathogens: Methods and compositions are disclosed for detecting and depleting cells infected with bacteria of the Chlamydiaceae family from a biological sample. Compositions include, for example, an immunoglobulin constant region polypeptide linked to an imaging moiety or a bactericide. Methods include, for example, contacting a biological sample that includes chlamydia infected...

20060204436 - Tritiated growth hormone secretagogue mk-0677: The present invention relates to a tritiated growth hormone secretagogue which can be used for the identification of compounds capable of binding to growth hormone secretagogue receptors, or of compounds having activity as growth hormone secretagogues....

20060204437 - Chlorin and bacteriochlorin-based difunctional aminophenyl dtpa and n2s2 conjugates for mr contrast media and radiopharmaceuticals: where R1, R2, R2a R3, R3a R4, R5, R5a R6, R7, R7a, and R8 cumulatively contain at least two functional groups that will complex or combine with an MR imaging enhancing element or ion. The compound is intended to include such complexes and combinations and includes the use of such...

20060204439 - Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol: The invention relates to techniques for measuring and comparing relative molecular flux rates of different biological molecules by administering isotope-labeled water to one or more tissues or individuals and comparing the molecular flux rates of two or more biological molecules, including biological molecules in different chemical classes. The methods find...

20060204438 - Water soluble iron oxide nanoparticles and a method of its preparation: This invention relates to water soluble iron oxide nanoparticles and a method of its preparation. More specifically, this invention relates to a method of manufacturing water soluble iron oxide nanoparticles uniform in size by coating polyvinylpyrolidone, a biocompatible polymer that can be intravenously administered via thermal decomposition, on the surface...

20060204442 - Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents: The invention relates to magnetically targetable particles comprising at least one magnetic component The particles are capable of delivering selectively to a site or organ a biologically active substance for in vivo medical diagnosis and/or treatment. The particles are prepared by many processes such as encapsulation processes. Also described are...

20060204443 - Methods for tumor treatment using dendrimer conjugates: Methods are disclosed for treating a tumor. A dendrimer conjugate is administered to a subject having a tumor. The dendrimer of the dendrimer conjugate is a generation 5 DAB, generation 2 polylysine, or generation 6-8 PAMAM dendrimer. The dendrimer conjugate comprises an effective amount of an anti-tumor agent. The anti-tumor...

20060204444 - Protein cages for the delivery of medical imaging and therapeutic agents: The present invention is directed to novel compositions and methods utilizing delivery agents comprising protein cages, medical imaging agents and therapeutic agents....

20060204445 - Cell scaffold matrices with image contrast agents: The invention is directed to methods and compositions for monitoring remodeling of an artificial tissue construct using image or contrast enhancing agents. The invention allows the growth, development, and remodeling of the artificial tissue to be monitored....

20060204440 - Radio-opaque polymeric biomaterials: Iodinated and/or brominated derivatives of aromatic dihydroxy monomers are prepared and polymerized to form radio-opaque polymers. The monomers may also be copolymerized with other dihydroxy monomers. The iodinated and brominated aromatic dihydroxy monomers can be employed as radio-opacifying, biocompatible non-toxic additives for other polymeric biomaterials. Radio-opaque medical implants and drug...

20060204441 - Cell scaffold matrices with incorporated therapeutic agents: The invention is directed to methods and compositions for preparing matrices for controlled delivery of at least one therapeutic or biological agent to a target site in a subject. This is accomplished using nanoparticles coupled to the therapeutic or biological agent that are incorporated within the matrix or reacted on...

20060204447 - Small particle liposome aerosols for delivery of anticancer drugs: Provided herein is a method of treating primary lung cancer or metastatic cancer to the lung in an individual by delivering at least once to the respiratory tract of the individual via inhalation a nebulized liposomal aerosol comprising a dilauroylphosphatidylcholine liposome containing camptothecin or a derivative thereof in an amount...

20060204446 - Topical immunotherapy and compositions for use therein: The present invention is concerned with the use of at least one immunosuppressant, or a pharmaceutically acceptable salt, solvate of physiologically functional derivative thereof, in the treatment of topical immune disorders of the scalp, and scalp conditions, and compositions suitable for such use....

20060204449 - Nasal pharmaceutical composition of piribedil: The present invention relates to a pharmaceutical composition for the administration, by the nasal route, of piribedil in solution or in powder form....

20060204450 - Pharmaceutical compositions based on anticholinergics and pde 5-inhibitors: The present invention relates to novel pharmaceutical compositions based on anticholinergics and PDE 5-inhibitors, processes for preparing them and their use in the treatment of pulmonary hypertension....

20060204448 - Powdery preparation for nasal administration: According to the present invention, a powdery preparation for nasal administration comprising a physiologically active substance, a non-water-absorbing and hardly water-soluble powder(s) and one or two selected from the group consisting of a mucolytic agent and a nonionic surfactant is provided....

20060204451 - Chewing gum in the form of multi-layer tablets: Disclosed are tablets having a sandwich-like structure comprising at least one inner layer of gum base containing one or more active pharmaceutical, dietetic or nutritional ingredients and two non-contigous outer layers comprising antiadhesion excipients and compression adjuvants preventing the adhesion to the punches of the tabletting machine and possibly active...

20060204452 - Antimicrobial film-forming dental compositions and methods: The present application provides dental compositions, methods of making, and methods of using dental compositions that include an antimicrobial lipid component and a water-dispersible, polymeric film-former....

20060204453 -